Edwards Lifesciences (EW) — insider trading
Health Care
Edwards Lifesciences (EW) has 21 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 21 (latest 2026-07-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-11 | Bruls Annette | Officer (CVP, EMEACLA) | Shares withheld for taxes / exercise cost | 109 | $92.21 | $10.1K | Form 4 |
| 2026-07-10 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion (derivative) | 619 | $0.00 | $0 | Form 4 |
| 2026-07-10 | Lippis Daniel J. | Officer (CVP, TAVR) | Open-market sale | 619 | $91.70 | $56.8K | Form 4 |
| 2026-07-10 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion | 619 | $72.68 | $45.0K | Form 4 |
| 2026-07-09 | Mistras Theodora | Officer (CVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 12,325 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Mistras Theodora | Officer (CVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 61,800 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Mistras Theodora | Officer (CVP, Chief Financial Officer) | Grant / award / vesting | 12,325 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Mistras Theodora | Officer (CVP, Chief Financial Officer) | Grant / award / vesting | 87,595 | $0.00 | $0 | Form 4 |
| 2026-07-07 | Lippis Daniel J. | Officer (CVP, TAVR) | Shares withheld for taxes / exercise cost | 377 | $95.18 | $35.9K | Form 4 |
| 2026-06-30 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion (derivative) | 619 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Lippis Daniel J. | Officer (CVP, TAVR) | Open-market sale | 619 | $91.40 | $56.6K | Form 4 |
| 2026-06-30 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion | 619 | $72.68 | $45.0K | Form 4 |
| 2026-06-17 | Zovighian Bernard J | Director, Officer (CEO) | Open-market sale | 523 | $87.92 | $46.0K | Form 4 |
| 2026-05-29 | Dahl Andrew M. | Officer (SVP, Corporate Controller) | Open-market sale | 568 | $86.08 | $48.9K | Form 4 |
| 2026-05-27 | BOBO DONALD E JR | Officer (CVP,Strategy/Corp Development) | Open-market sale | 23,145 | $86.42 | $2.00M | Form 4 |
| 2026-05-22 | Chopra Daveen | Officer (CVP, TMTT & Surgical) | Open-market sale | 1,500 | $84.60 | $126.9K | Form 4 |
| 2026-05-18 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion (derivative) | 620 | $0.00 | $0 | Form 4 |
| 2026-05-18 | Lippis Daniel J. | Officer (CVP, TAVR) | Open-market sale | 620 | $81.14 | $50.3K | Form 4 |
| 2026-05-18 | Lippis Daniel J. | Officer (CVP, TAVR) | Option exercise / conversion | 620 | $72.68 | $45.1K | Form 4 |
| 2026-05-15 | BOBO DONALD E JR | Officer (CVP,Strategy/Corp Development) | Open-market sale | 8,000 | $81.82 | $654.6K | Form 4 |
| 2026-05-15 | BOBO DONALD E JR | Officer (CVP,Strategy/Corp Development) | Open-market sale | 9,968 | $82.07 | $818.1K | Form 4 |
Ask the chat about EW's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Edwards Lifesciences (EW).
Last updated 2026-07-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.